Attenuation of scopolamine-induced cognitive dysfunction by obovatol

Archives of Pharmacal Research

Volumn 35, Issue 7, 2012, Pages 1279-1286

  Choi, Dong Young ^a   Lee, Young Jung ^a   Lee, Sun Young ^a   Lee, Yoot Mo ^a   Lee, Hyun Hee ^a   Choi, Im Seop ^a   Oh, Ki Wan ^a   Han, Sang Bae ^a   Nam, Sang Yoon ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Acetylcholine esterase; Alzheimer's disease; Memory; Obovatol; Scopolamine; Secretase

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BETA SECRETASE; HERBACEOUS AGENT; OBOVATOL; SCOPOLAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; ENZYME ACTIVITY; HIPPOCAMPUS; LEARNING DISORDER; MAGNOLIA OBOVATA; MAGNOLIACEAE; MALE; MAZE TEST; MOUSE; NONHUMAN; PASSIVE AVOIDANCE;

ACETYLCHOLINESTERASE; AMNESIA; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GPI-LINKED PROTEINS; HIPPOCAMPUS; MALE; MEMORY; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; NOOTROPIC AGENTS; PHENYL ETHERS; SCOPOLAMINE HYDROBROMIDE; TIME FACTORS;

EID: 84864954221     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-012-0719-1     Document Type: Article

References (35)

1. Ahmed, T. and Gilani, A. H., Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer's disease. Pharmacol. Biochem. Behav., 91, 554-559 (2009).
2. Auld, D. S., Kornecook, T. J., Bastianetto, S., and Quirion, R., Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol., 68, 209-245 (2002). (Pubitemid 35346805)
3. Bailey, J. A., Ray, B., Greig, N. H., and Lahiri, D. K., Rivastigmine lowers Abeta and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS One, 6, e21954 (2011).
4. Beatty, W. W., Butters, N., and Janowsky, D. S., Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav. Neural Biol., 45, 196-211 (1986). (Pubitemid 16164035)
5. Choi, D. Y., Lee, J. W., Lin, G., Lee, Y. J., Ban, J. O., Lee, Y. H., Choi, I. S., Han, S. B., Jung, J. K., Lee, W. S., Lee, S. H., Kwon, B. M., Oh, K. W., and Hong, J. T., Obovatol improves cognitive functions in animal models for Alzheimer's disease. J. Neurochem., 120, 1048-1059 (2012a).
6. Choi, D. Y., Lee, J. W., Lin, G., Lee, Y. K., Lee, Y. H., Choi, I. S., Han, S. B., Jung, J. K., Kim, Y. H., Kim, K. H., Oh, K. W., Hong, J. T., and Lee, M. S., Obovatol attenuates LPSinduced memory impairments in mice via inhibition of NF-kappaB signaling pathway. Neurochem. Int., 60, 68-77 (2012b).
7. Cole, S. L. and Vassar, R., The role of amyloid precursor protein processing by BACE1, the beta-secretase, in Alzheimer disease pathophysiology. J. Biol. Chem., 283, 29621-29625 (2008).
8. Ellman, G. L., Courtney, K. D., Andres, V., Jr., and Feather-Stone, R. M., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 7, 88-95 (1961).
9. Ensinger, H. A., Doods, H. N., Immel-Sehr, A. R., Kuhn, F. J., Lambrecht, G., Mendla, K. D., Muller, R. E., Mutschler, E., Sagrada, A., Walther, G., and Hammer, R., WAL 2014-a muscarinic agonist with preferential neuron-stimulating properties. Life Sci., 52, 473-480 (1993).
10. Glabe, C. G., Structural classification of toxic amyloid oligomers. J. Biol. Chem., 283, 29639-29643 (2008).
11. Ho, K. Y., Tsai, C. C., Chen, C. P., Huang, J. S., and Lin, C. C., Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother. Res., 15, 139-141 (2001).
12. Hock, C., Maddalena, A., Heuser, I., Naber, D., Oertel, W., Von Der Kammer, H., Wienrich, M., Raschig, A., Deng, M., Growdon, J. H., and Nitsch, R. M., Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer's disease. Ann. N. Y. Acad. Sci., 920, 285-291 (2000). (Pubitemid 32056583)
13. Huber, K. and Superti-Furga, G., After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg. Med. Chem., 19, 3616-3624 (2011).
14. Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H. P., and Van Den Bussche, H., Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ, 331, 321-327 (2005).
15. Kwon, S. H., Lee, H. K., Kim, J. A., Hong, S. I., Kim, H. C., Jo, T. H., Park, Y. I., Lee, C. K., Kim, Y. B., Lee, S. Y., and Jang, C. G., Neuroprotective effects of chlorogenic acid on scopolamine-induced amnesia via anti-acetylcholinesterase and anti-oxidative activities in mice. Eur. J. Pharmacol., 649, 210-217 (2010).
16. Lee, B., Shim, I., Lee, H., and Hahm, D. H., Rehmannia glutinosa ameliorates scopolamine-induced learning and memory impairment in rats. J. Microbiol. Biotechnol., 21, 874-883 (2011).
17. Lee, S. K., Kim, H. N., Kang, Y. R., Lee, C. W., Kim, H. M., Han, D. C., Shin, J., Bae, K., and Kwon, B. M., Obovatol inhibits colorectal cancer growth by inhibiting tumor cell proliferation and inducing apoptosis. Bioorg. Med. Chem., 16, 8397-8402 (2008).
18. Lee, Y. K., Choi, I. S., Kim, Y. H., Kim, K. H., Nam, S. Y., Yun, Y. W., Lee, M. S., Oh, K. W., and Hong, J. T., Neurite outgrowth effect of 4-O-methylhonokiol by induction of neurotrophic factors through ERK activation. Neurochem. Res., 34, 2251-2260 (2009a).
19. Lee, Y. K., Yuk, D. Y., Kim, T. I., Kim, Y. H., Kim, K. T., Kim, K. H., Lee, B. J., Nam, S. Y., and Hong, J. T., Protective effect of the ethanol extract of Magnolia officinalis and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. J. Nat. Med., 63, 274-282 (2009b).
20. Lee, Y. K., Song, J. K., Choi, I. S., Jeong, J. H., Moon, D. C., Yun, Y. P., Han, S. B., Oh, K. W., and Hong, J. T., Neurotrophic activity of obovatol on the cultured embryonic rat neuronal cells by increase of neurotrophin release through activation of ERK pathway. Eur. J. Pharmacol., 649, 168-176 (2010).
21. Lin, L., Leblanc, C. J., Deacon, T. W., and Isacson, O., Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. Neuroreport, 9, 547-552 (1998). (Pubitemid 28109220)
22. Liskowsky, W. and Schliebs, R., Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int. J. Dev. Neurosci., 24, 149-156 (2006). (Pubitemid 43294621)
23. Matsui, N., Takahashi, K., Takeichi, M., Kuroshita, T., Noguchi, K., Yamazaki, K., Tagashira, H., Tsutsui, K., Okada, H., Kido, Y., Yasui, Y., Fukuishi, N., Fukuyama, Y., and Akagi, M., Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice. Brain Res., 1305, 108-117 (2009).
24. Messamore, E., Warpman, U., Ogane, N., and Giacobini, E., Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacology, 32, 745-750 (1993). (Pubitemid 23227659)
25. Muller, D. M., Mendla, K., Farber, S. A., and Nitsch, R. M., Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci., 60, 985-991 (1997). (Pubitemid 27165566)
26. Nitsch, R. M., Deng, M., Tennis, M., Schoenfeld, D., and Growdon, J. H., The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol., 48, 913-918 (2000).
27. Nitsch, R. M., Slack, B. E., Wurtman, R. J., and Growdon, J. H., Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science, 258, 304-307 (1992).
28. Nordberg, A. and Svensson, A. L., Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf., 19, 465-480 (1998). (Pubitemid 29015406)
29. Ock, J., Han, H. S., Hong, S. H., Lee, S. Y., Han, Y. M., Kwon, B. M., and Suk, K., Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. Br. J. Pharmacol., 159, 1646-1662 (2010).
30. Park, S. J., Kim, D. H., Jung, J. M., Kim, J. M., Cai, M., Liu, X., Hong, J. G., Lee, C. H., Lee, K. R., and Ryu, J. H., The ameliorating effects of stigmasterol on scopolamine-induced memory impairments in mice. Eur. J. Pharmacol., 676, 64-70 (2012).
31. Petersen, R. C., Scopolamine induced learning failures in man. Psychopharmacology (Berl.), 52, 283-289 (1977). (Pubitemid 8097255)
32. Preston, G. C., Brazell, C., Ward, C., Broks, P., Traub, M., and Stahl, S. M., The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. J. Psychopharmacol., 2, 67-79 (1988). (Pubitemid 18267268)
33. Seo, J. J., Lee, S. H., Lee, Y. S., Kwon, B. M., Ma, Y., Hwang, B. Y., Hong, J. T., and Oh, K. W., Anxiolytic-like effects of obovatol isolated from Magnolia obovata: involvement of GABA/benzodiazepine receptors complex. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 1363-1369 (2007). (Pubitemid 47302547)
34. Uriarte-Pueyo, I. and Calvo, M. I., Flavonoids as acetylcholinesterase inhibitors. Curr. Med. Chem., 18, 5289-5302 (2011).
35. Weinreb, O., Amit, T., Mandel, S., and Youdim, M. B., Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr., DOI 10.1007/s12263-009-0143-4 (2009).